Noida, UP -- (SBWIRE) -- 11/07/2014 -- According to a new research report by RNCOS entitled, “Global Gene Therapy Market Outlook 2018”, the advancement of gene therapy for eye disorders is likely to prove to be one of the greatest medical advances in the coming years, as industry participants are increasingly strengthening the research-based approach to develop newer products. The treatment involves inserting a functional gene into the eye that restores vision without causing any harm to the neighboring cells.

Both public and private players are focusing on developing gene therapies for genetic form of blindness. The Children's Hospital of Philadelphia’s spin out company, Spark Therapeutics, is on the verge of gaining FDA approval for developing first gene therapy against genetic form of blindness. Similarly, trials with gene therapies developed by Sanofi, Oxford Biomedica, Oxford University and Lion’s research institute are offering hope to improve vision in a number of patients who would have otherwise gone blind.

The number of clinical trials since 2004 have showcased an irregular trend. This is due to the failure of most of the trials during the early (Phase I/II) or late phase (III) of clinical pipeline. Failure of Vical’s gene therapy Allovectin-7 in late stage was one of the examples observed last year. But according to the latest report by RNCOS, the gene therapy advanced stage trial products such as Collategene, and Generx would be promising to the industry’s growth. With the entry of new gene therapy products such as Glybera, this biotech niche would be expected to capture major market attention.

The report is spread in over 120 pages and provides an in-depth research and rational analysis of the global gene therapy market. A brief overview of the key geographies in the gene therapy segment and the regulatory scenario governing the industry has also been included in the study to present a balanced outlook. The report covers how major trends and drivers, including nanotechnology, advanced therapies to treat chronic diseases etc., will propel the industry’s growth. With a view to understand the competitive landscape, the profiles of key market players are included in the report to present a complete picture of the global gene therapy market.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM715.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.